论著

8例儿童IgA肾病合并膜性肾病的临床病理学特征及预后分析:回顾性病例系列报告

  • 林媛 ,
  • 李华荣 ,
  • 陈朝英
展开
  • 首都医科大学附属首都儿童医学中心肾脏内科 (北京 100020)
陈朝英 电子信箱:chenchaoying484@aliyun.com

收稿日期: 2025-08-25

  录用日期: 2026-01-06

  网络出版日期: 2026-03-06

基金资助

北京市属医院科研培育计划项目(PX2023050)

Clinicopathological features and prognosis of eight children with coexisting IgA nephropathy and membranous nephropathy: retrospective case series report

  • LIN Yuan ,
  • LI Huarong ,
  • CHEN Chaoying
Expand
  • Capital Center for Children’s Health, Capital Medical University, Beijng 100020, China

Received date: 2025-08-25

  Accepted date: 2026-01-06

  Online published: 2026-03-06

摘要

目的 总结并分析8例儿童IgA肾病(IgAN)合并膜性肾病(MN)的临床与病理特征及预后。方法 本研究为回顾性病例系列,纳入2014年1月至2024年12月在首都医科大学附属首都儿童医学中心经肾活检确诊的8例IgAN合并MN(IgAN+MN)患儿,收集临床与病理资料,并结合国内外文献进行对比分析。结果 8例患儿中男4例、女4例,中位发病年龄7岁。主要表现为肉眼血尿和/或蛋白尿,50%伴肾病综合征,87.5%出现血尿。病理多为系膜增生性肾小球肾炎伴膜性病变,免疫荧光均示IgA系膜沉积及IgG基底膜沉积。所有患儿接受糖皮质激素联合免疫抑制剂治疗,完全缓解率100%,中位缓解时间2(1~5)个月。结论 儿童 IgAN+MN兼具IgAN+MN的临床表型,对激素及免疫抑制治疗反应良好,短期预后佳。早期诊断与积极治疗可改善预后,长期随访仍需关注复发及慢性进展。

本文引用格式

林媛 , 李华荣 , 陈朝英 . 8例儿童IgA肾病合并膜性肾病的临床病理学特征及预后分析:回顾性病例系列报告[J]. 临床儿科杂志, 2026 , 44(3) : 202 -208 . DOI: 10.12372/jcp.2026.25e1036

Abstract

Objective To summarize and analyze the clinical and pathological characteristics and short-term outcomes of eight children diagnosed with concomitant IgA nephropathy (IgAN) and membranous nephropathy (MN). Methods This retrospective case series included eight pediatric patients with biopsy-proven IgAN+MN between January 2014 and December 2024. Clinical manifestations, laboratory findings, and renal histopathology were reviewed and summarized, and the results were compared with those reported in the literature. Results The cohort comprised eight children (4 boys and 4 girls), with a median age at onset of 7 years. The main clinical presentations were gross hematuria and/or proteinuria. Nephrotic syndrome occurred in 50% of patients, and hematuria was observed in 87.5%. Renal pathology predominantly demonstrated mesangial proliferative glomerulonephritis accompanied by early- to intermediate-stage membranous lesions. Immunofluorescence showed IgA deposition in the mesangium and IgG deposition along the glomerular basement membrane. All patients were treated with glucocorticoids in combination with immunosuppressive agents. Complete remission was achieved in all cases (100%), with a median time to remission of 2 months (range, 1-5 months). Conclusion Pediatric IgAN+MN shows overlapping clinical phenotypes of IgAN and MN. Treatment with glucocorticoids plus immunosuppressants appears to be highly effective, and short-term prognosis is favorable. Early diagnosis and active intervention may improve outcomes; however, long-term follow-up is needed to monitor relapse and chronic progression.

参考文献

[1] Tan L, Jin LH, Wang YQ, et al. Clinical features, pathological characteristics, and prognosis of patients with IgA nephropathy complicated with nephrotic syndrome[J]. Sci Rep, 2025, 15(1): 1804.
[2] Mao Y, Zhou W, Zhou Z, et al. Treatment and outcome of IgA nephropathy in children from one single center experience[J]. BMC Pediatr, 2023, 23(1): 377.
[3] 张艳敏, 刘玉洁, 贾东华, 等. 儿童特发性膜性肾病的临床病理特点及治疗[J]. 罕少疾病杂志, 2025, 32(02): 15-7.
  Zhang YM, Liu YJ, Jia DH, et al. Clinicopathological characteristics and treatment of idiopathic membranous nephropathy in children[J]. Hanshaojibing Zazhi, 2025, 32(2): 15-17.
[4] 王羽晴, 朱琳, 周萍. 黑龙江省单中心785例儿童肾活检病理分析(2002年-2019年) [J]. 肾脏病与透析肾移植杂志, 2020, 29(4): 323-7.
  Wang YQ, Zhu L, Zhou P. Pathological analysis of 785 pediatric renal biopsies from a single center in Heilongjiang Province (2002-2019) [J]. Shenzangbing Yu Touxi Shenyizhi Zazhi, 2020, 29(4): 323-327.
[5] Ramachandran R, Nayak S, Kumar V, et al. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia[J]. Pediatr Nephrol, 2021, 36(5): 1217-1226.
[6] Huang G, Liu F, Yu L, et al. Pediatric membranous nephropathy: In the novel antigens era[J]. Front Immunol, 2022, 13: 962502.
[7] Nishida M, Kato R, Hamaoka K. Coexisting Membranous Nephropathy and IgA Nephropathy[J]. Fetal Pediatr Pathol, 2015, 34(6): 351-354.
[8] Chen P, Shi SF, Qu Z, et al. Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy[J]. Ren Fail, 2018, 40(1): 213-218.
[9] Lee SM. Prognostic indicators of progressive renal disease in IgA nephropathy: emergence of a new histologic grading system[J]. Am J Kidney Dis, 1997, 29(6): 953-958.
[10] Marx BE, Marx M. Prediction in idiopathic membranous nephropathy[J]. Kidney Int, 1999, 56(2): 666-673.
[11] Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns[J]. Kidney Int, 2024, 105(4): 684-701.
[12] Zhou N, Wang H, Wang XY, et al. Characteristics of children with IgA nephropathy[J]. Pediatr Res, 2023, 93(3): 715-719.
[13] Wang R, Wang M, Xia Z, et al. Long-term renal survival and related risk factors for primary membranous nephropathy in Chinese children: a retrospective analysis of 217 cases[J]. J Nephrol, 2021, 34(2): 589-596.3
[14] 王忍, 王美秋, 高春林, 等. 伴C1q沉积的儿童原发性膜性肾病的临床特点及预后[J]. 中华实用儿科临床杂志, 2021, 36(21): 1610-1613.
  Wang R, Wang MQ, Gao CL, et al. Clinical features and prognosis of pediatric primary membranous nephropathy with C1q deposition[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2021, 36(21): 1610-1613.
[15] Menon S, Valentini RP. Membranous nephropathy in children: clinical presentation and therapeutic approach[J]. Pediatr Nephrol, 2010, 25(8): 1419-1428.
[16] Shima Y, Nakanishi K, Sato M, et al. IgA nephropathy with presentation of nephrotic syndrome at onset in children[J]. Pediatr Nephrol, 2017, 32(3): 457-465.
[17] Valentini RP, Mattoo TK, Kapur G, et al. Membranous glomerulonephritis: treatment response and outcome in children[J]. Pediatr Nephrol, 2009, 24(2): 301-308.
[18] Aziz M, Ehsan A, Mubarak M, et al. Clinicopathologic features and the association with short-term outcome of primary membranous nephropathy in children: a single-center study from pakistan[J]. Saudi J Kidney Dis Transpl, 2020, 31(5): 1078-1084.
[19] 徐可, 王芳, 王中华, 等. 儿童原发膜性肾病肾小球C1q或IgA沉积的意义探讨[J]. 中华儿科杂志, 2022, 60(9): 901-907.
  Xu K, Wang F, Wang ZH, et al. Significance of glomerular C1q or IgA deposition in pediatric primary membranous nephropathy[J]. Zhonghua Erke Zazhi, 2022, 60(9): 901-907.
[20] Sawamura M, Komatsuda A, Kaga H, et al. Membranous nephropathy with solitary polyclonal IgA deposition: A case report and literature review[J]. Clin Nephrol Case Stud, 2019, 7: 60-65.
[21] Knoppova B, Reily C, King RG, et al. Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment[J]. J Clin Med, 2021, 10(19): 4501.
[22] Medjeral-Thomas NR, Cook HT, Pickering MC. Complement activation in IgA nephropathy[J]. Semin Immunopathol, 2021, 43(5): 679-690.
[23] Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1): 11-21.
[24] Teisseyre M, Beyze A, Perrochia H, et al. C5b-9 glomerular deposits are associated with poor renal survival in membranous nephropathy[J]. Kidney Int Rep, 2022, 8(1): 103-114.
[25] Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy[J]. Kidney Int, 2020, 97(1): 163-174.
[26] Sethi S, Beck LH Jr, Glassock RJ, et al. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification[J]. Kidney Int, 2023, 104(6): 1092-1102.
[27] Doi T, Mayumi M, Kanatsu K, et al. Distribution of IgG subclasses in membranous nephropathy[J]. Clin Exp Immunol, 1984, 58(1): 57-62.
[28] He JW, Cui DF, Zhou XJ, et al. Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome?[J]. Front Immunol, 2022, 13: 846323.
[29] D'Amico G, Colasanti G, Barbiano di Belgioioso G, et al. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients[J]. Semin Nephrol, 1987, 7(4): 355-358.
[30] Hastings MC, Bursac Z, Julian BA, et al. Life expectancy for patients from the southeastern united states with IgA nephropathy[J]. Kidney Int Rep, 2017, 3(1): 99-104.
文章导航

/